Spinraza (nusinersen) is a brand-name drug that’s prescribed for spinal muscular atrophy (SMA) in adults and children. Spinraza comes as a spinal injection that’s given by a healthcare professional ...

Biogen BIIB announced positive initial data from the pivotal cohort (Part B) of its mid to late-stage study evaluating the safety and efficacy of a higher dose regimen of Spinraza (nusinersen) in ...

(RTTNews) - Biogen Inc. (BIIB) announced that the European Commission has granted marketing authorization for a high dose regimen of SPINRAZA (nusinersen) which is comprised of 50 mg/5 mL and 28 mg/5 ...

Biogen said that new data examining its already approved spinal muscular atrophy treatment Spinraza (nusinersen) indicates that a higher dose than currently approved may lead to better improvement in ...

Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA 1 ...

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)New Phase 1b ...

Please provide your email address to receive an email when new articles are posted on . Topline data from an ongoing clinical trial of a higher dose regimen of Spinraza in treatment-naive, symptomatic ...

DEVOTE trial to evaluate safety and even greater efficacy of a higher dose of SPINRAZA in the treatment of SMA; well-established safety profile supports exploration of potential benefits Long-term ...

A high-dose version of Biogen’s Spinraza (nusinersen) could soon be available in Europe, after a panel recommended the formulation’s approval. Spinraza is already approved in multiple regions, ...

Biogen has secured European regulatory approval for a high-dose regimen of its Spinraza drug for the neuromuscular disease spinal muscular atrophy, or SMA. Biogen on Monday said the European ...